Re: USA ZHCLF investors
in response to
by
posted on
Oct 30, 2022 04:07PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Koo - I can't argue with that but that is what it is. When the RPSs were awarded to Zenith as a corp. rather than individual Zenith shareholders, that is the result.